



CS/BSE/NSE/PR/2017-2018  
August 17, 2017

**To**  
**The Manager**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**To**  
**The General Manager**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**Stock Code: SUVEN - EQ**

**Stock Code: 530239**

Dear Sir/Madam,

**Sub: Press Release**

.....  
With reference to above subject, please find enclosed Press Release of our company titled **“Suvan Life Sciences secures Process Patents in Europe, Japan and New Zealand”**

This is for your information and record.

Thanking You,  
Yours faithfully,  
For **Suvan Life Sciences Limited**

A handwritten signature in black ink, appearing to read "K. Hanumantha Rao".

**K. Hanumantha Rao**  
Company Secretary

## **Suvan Life Sciences Limited**

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor Road No.5 I Avenue 7  
Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suvan.com](mailto:info@suvan.com) website: [www.suvan.com](http://www.suvan.com)



## News Release

### Suven Life Sciences secures Process Patents in Europe, Japan and New Zealand

**HYDERABAD, INDIA (August 17, 2017) – Suven Life Sciences Ltd (Suven)** announces today that the grant of **one (1) process patent from Europe (3077375), one (1) process patent from Japan (6151453) and one (1) process patent from New Zealand (719671)** corresponding to the New Chemical Entities (NCEs) which are for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2034.

These process patents are for our pipeline compounds which are in **the class of selective 5-HT<sub>6</sub> compounds** and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Venkat Jasti, CEO of Suven.

#### About Suven Life Sciences

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, Phase 1 completed SUVN-D4010 and Phase 1 commenced SUVN-911.

In addition to these clinical compounds the Company has nine (9) internally-discovered therapeutic drug candidates currently in various stages of pre-clinical development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.

For more information please visit our Web site at <http://www.suven.com>

#### Risk Statement:

*Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*

### Suven Life Sciences Limited

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor, Road No.5 I Avenue 7  
Banjara Hills I Hyderabad – 500 034 I Telangana I India I CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: [info@suven.com](mailto:info@suven.com) website: [www.suven.com](http://www.suven.com)